Which patients benefit most from early thrombolytic therapy with intracoronary streptokinase?
- 1 December 1986
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 74 (6) , 1379-1389
- https://doi.org/10.1161/01.cir.74.6.1379
Abstract
The effect of thrombolysis in acute myocardial infarction on enzymatic infarct size, left ventricular function, and early mortality was studied in subsets of patients in a randomized trial. Early thrombolytic therapy with intracoronary streptokinase (152 patients) or with intracoronary streptokinase preceded by intravenous streptokinase (117 patients) was compared with conventional treatment (264 patients). All 533 patients were admitted to the coronary care unit within 4 hr after onset of symptoms indicative of acute myocardial infarction. Four hundred eighty-eight patients were eligible for this detailed analysis, and 245 of these were allocated to thrombolytic therapy and 243 to conventional treatment. Early angiographic examinations were performed in 212 patients allocated to thrombolytic therapy. Patency of the infarct-related artery was achieved in 181 patients (85%). Enzymatic infarct size, as measured from cumulative alpha-hydroxybutyrate dehydrogenase release, was smaller in patients allocated to thrombolytic therapy (median 760 vs 1170 U/liter in control patients, p = .0001). Left ventricular ejection fraction measured by radionuclide angiography before discharge from the hospital was higher after thrombolytic therapy (median 50% vs 43% in control patients, p = .0001). Three month mortality was lower in patients allocated to thrombolytic therapy (6% vs 14% in the control group, p = .006). With the use of multivariate regression analysis, infarct size limitation, improvement in left ventricular ejection fraction, and three month mortality were predicted by sum of the ST segment elevation, time from onset of symptoms to admission, and Killip class at admission. Thrombolysis was most effective in patients admitted within 2 hr after onset of symptoms and in patients with a sum of ST segment elevation of 1.2 mV or more. On the other hand, no beneficial effects of streptokinase on enzymatic infarct size, left ventricular function, or mortality were observed in the subset of patients with a sum of ST segment elevation of less than 1.2 mV who were admitted between 2 and 4 hr after onset of symptoms.This publication has 30 references indexed in Scilit:
- Effects of early intracoronary streptokinase on infarct size estimated from cumulative enzyme release and on enzyme release rate: A randomized trial of 533 patients with acute myocardial infarctionAmerican Heart Journal, 1986
- A Prospective Trial of Intravenous Streptokinase in Acute Myocardial Infarction (I.S.A.M.)New England Journal of Medicine, 1986
- The Western Washington Randomized Trial of Intracoronary Streptokinase in Acute Myocardial InfarctionNew England Journal of Medicine, 1985
- Effects of Intracoronary Streptokinase and Intracoronary Nitroglycerin Infusion on Coronary Angiographic Patterns and Mortality in Patients with Acute Myocardial InfarctionNew England Journal of Medicine, 1984
- Long-term follow-up after intracoronary streptokinase for myocardial infarction: A randomized, controlled studyAmerican Heart Journal, 1984
- Western Washington Randomized Trial of Intracoronary Streptokinase in Acute Myocardial InfarctionNew England Journal of Medicine, 1983
- A Randomized Trial of Intracoronary Streptokinase in the Treatment of Acute Myocardial InfarctionNew England Journal of Medicine, 1983
- Intracoronary Fibrinolytic Therapy in Acute Myocardial InfarctionNew England Journal of Medicine, 1983
- Intravenous short-term infusion of streptokinase in acute myocardial infarction.Circulation, 1983
- A New Design for Randomized Clinical TrialsNew England Journal of Medicine, 1979